Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00321438 · ClinicalTrials.gov registry record
Observational Study of HIV-Infected Subjects With X4-Tropic or Non-Phenotypeable Virus
A clinical trial, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- 150
- Enrollment target
NCT00321438: Clinical Trial study, sponsored by GlaxoSmithKline.
NCT00321438 is a clinical trial that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 150 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00321438 was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- 150 participants
- Enrollment target
Study Summary
The purpose of this study is to measure viral tropism over time in subjects with X4-tropic or non-phenotypeable virus while receiving standard of care therapy. This is an observational study. No investigational treatment will be administered through this study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2005-07 |
Why NCT00321438 stopped before completion
NCT00321438 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00321438 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00321438 about?
NCT00321438 is a clinical study titled "Observational Study of HIV-Infected Subjects With X4-Tropic or Non-Phenotypeable Virus". The purpose of this study is to measure viral tropism over time in subjects with X4-tropic or non-phenotypeable virus while receiving standard of care therapy. This is an observational study. No investigational treatment will be administered through this study.
What is the current status of trial NCT00321438?
This trial is currently terminated. The enrollment target is 150 participants. The study started on 2005-07.
Who is sponsoring clinical trial NCT00321438?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia